In previous investigations, we investigated the impact of ABCG2 on concentration of allopurinol, oxypurinol (the active metabolite of allopurinol), and D-ribose allopurinol, as well as allopurinol dosing.
Here, we perform a GWAS of these endpoints using GWAS data from the GSA chip to identify novel genetic determinants of allopurinol pharmacokinetics and dosing.